(Q37349715)

19 August 2017

1 reference

title

New therapeutic strategies for treatment of inflammatory bowel disease (English)

1 reference

inflammatory bowel diseases

19 August 2017

main subject

0 references

inflammation

0 references

author name string

R Atreya

series ordinal

1

1 reference

19 August 2017

M F Neurath

series ordinal

2

1 reference

19 August 2017

publication date

5 March 2008

1 reference

19 August 2017

1 reference

19 August 2017

volume

1

1 reference

19 August 2017

issue

3

1 reference

19 August 2017

page(s)

175-182

1 reference

https://scigraph.springernature.com/pub.10.1038/mi.2008.7

19 August 2017

exact match

0 references

cites work

Inflammatory bowel disease (1)

1 reference

Specific inhibition of c-Raf activity by semapimod induces clinical remission in severe Crohn's disease

21 January 2018

1 reference

Inflammatory Bowel Disease

21 January 2018

1 reference

7 January 2021

Inflammatory bowel disease: etiology and pathogenesis

1 reference

7 January 2021

Intestinal permeability in patients with Crohn's disease and ulcerative colitis and their first degree relatives

1 reference

7 January 2021

Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery

1 reference

7 January 2021

Inflammatory bowel disease: immunodiagnostics, immunotherapeutics, and ecotherapeutics

1 reference

7 January 2021

Cytokines in intestinal inflammation: pathophysiological and clinical considerations.

1 reference

7 January 2021

Regulation of T-cell apoptosis in inflammatory bowel disease: to die or not to die, that is the mucosal question

1 reference

7 January 2021

Lamina propria T cells in Crohn's disease and other gastrointestinal inflammation show defective CD2 pathway-induced apoptosis

1 reference

7 January 2021

Ligands working as receptors: reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system

1 reference

7 January 2021

Tumor necrosis factor signaling.

1 reference

7 January 2021

Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine

1 reference

7 January 2021

Mucosal inflammatory cytokine production by intestinal biopsies in patients with ulcerative colitis and Crohn's disease

1 reference

7 January 2021

Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease

1 reference

7 January 2021

Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease

1 reference

7 January 2021

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

1 reference

7 January 2021

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

1 reference

7 January 2021

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

1 reference

7 January 2021

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

1 reference

7 January 2021

Certolizumab pegol for the treatment of Crohn's disease

1 reference

7 January 2021

Maintenance therapy with certolizumab pegol for Crohn's disease

1 reference

7 January 2021

Infliximab for the treatment of fistulas in patients with Crohn's disease

1 reference

7 January 2021

Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial

1 reference

7 January 2021

Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway

1 reference

7 January 2021

Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease.

1 reference

7 January 2021

Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept

1 reference

7 January 2021

Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease

1 reference

7 January 2021

Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease

1 reference

7 January 2021

Transmembrane TNF-alpha, induction of apoptosis, and the efficacy of TNF-targeting therapies in Crohn's disease

1 reference

7 January 2021

Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha

1 reference

7 January 2021

Effects of infliximab on apoptosis and reverse signaling of monocytes from healthy individuals and patients with Crohn's disease.

1 reference

7 January 2021

Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents

1 reference

7 January 2021

Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease

1 reference

7 January 2021

Optimizing anti-TNF treatment in inflammatory bowel disease

1 reference

7 January 2021

In vivo single-photon emission computed tomography imaging of apoptosis in Crohn's disease and anti-tumour necrosis factor therapy

1 reference

7 January 2021

Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice

1 reference

7 January 2021

Evidence for continuous stimulation of interleukin-6 production in Crohn's disease

1 reference

7 January 2021

Relationship of functional and antigenic interleukin 6 to disease activity in inflammatory bowel disease

1 reference

7 January 2021

Frequently relapsing Crohn's disease is characterized by persistent elevation in interleukin-6 and soluble interleukin-2 receptor serum levels during remission.

1 reference

7 January 2021

A high serum concentration of interleukin-6 is predictive of relapse in quiescent Crohn's disease

1 reference

7 January 2021

Cytokine messenger RNA profiles in inflammatory bowel disease mucosa detected by polymerase chain reaction amplification

1 reference

7 January 2021

Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease

1 reference

7 January 2021

Elevation of interleukin-6 in inflammatory bowel disease is macrophage- and epithelial cell-dependent

1 reference

7 January 2021

Blockade of interleukin 6 trans signaling suppresses T-cell resistanceagainst apoptosis in chronic intestinal inflammation: Evidence in Crohn diseaseand experimental colitis in vivo

1 reference

7 January 2021

Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130

1 reference

7 January 2021

CIS3/SOCS3/SSI3 plays a negative regulatory role in STAT3 activation and intestinal inflammation

1 reference

7 January 2021

The soluble interleukin-6 receptor is generated by shedding

1 reference

7 January 2021

Soluble interleukin-6 receptors in inflammatory bowel disease: relation to circulating interleukin-6

1 reference

7 January 2021

IL-6 is required for the development of Th1 cell-mediated murine colitis

1 reference

7 January 2021

Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses

1 reference

7 January 2021

STAT3 activation via interleukin 6 trans-signalling contributes to ileitis in SAMP1/Yit mice

1 reference

7 January 2021

Treatment of Crohn's disease with anti-IL-6 receptor antibody.

1 reference

7 January 2021

Constitutive STAT3 Activation in Intestinal T Cells from Patients with Crohn's Disease

1 reference

7 January 2021

Interleukin-6 trans-signaling in inflammatory bowel disease

1 reference

7 January 2021

Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils.

1 reference

7 January 2021

STAT3 deletion during hematopoiesis causes Crohn's disease-like pathogenesis and lethality: a critical role of STAT3 in innate immunity

1 reference

7 January 2021

Growth hormone inhibits signal transducer and activator of transcription 3 activation and reduces disease activity in murine colitis.

1 reference

7 January 2021

Anti-interleukin 12 treatment regulates apoptosis of Th1 T cells in experimental colitis in mice.

1 reference

7 January 2021

An interleukin 12 p40-IgG2b fusion protein abrogates T cell mediated inflammation: anti-inflammatory activity in Crohn's disease and experimental colitis in vivo

1 reference

7 January 2021

Anti-interleukin-12 antibody for active Crohn's disease

1 reference

7 January 2021

IL-12 and IL-23: master regulators of innate and adaptive immunity.

1 reference

7 January 2021

New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions

1 reference

7 January 2021

IL-23 drives a pathogenic T cell population that induces autoimmune inflammation

1 reference

7 January 2021

Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells

1 reference

7 January 2021

Transforming growth factor-beta induces development of the T(H)17 lineage

1 reference

7 January 2021

1 reference

7 January 2021

IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6

1 reference

7 January 2021

Critical role of IL-17 receptor signaling in acute TNBS-induced colitis

1 reference

7 January 2021

Expression of interleukin-12-related cytokine transcripts in inflammatory bowel disease: elevated interleukin-23p19 and interleukin-27p28 in Crohn's disease but not in ulcerative colitis

1 reference

7 January 2021

Increased expression of interleukin 17 in inflammatory bowel disease

1 reference

7 January 2021

Both IL-12p70 and IL-23 are synthesized during active Crohn's disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody

1 reference

7 January 2021

Monoclonal Anti–Interleukin 23 Reverses Active Colitis in a T Cell–Mediated Model in Mice

1 reference

7 January 2021

Apoptosis as a therapeutic tool in rheumatoid arthritis

1 reference

7 January 2021

Identifiers

DOI

10.1038/MI.2008.7

1 reference

Dimensions Publication ID

19 August 2017

1040094887

0 references

1 reference